Genprex shares surge 11.37% after-hours after securing Japan and EU patents for Reqorsa gene therapy in combination with immunotherapies.

Genprex Inc. (NASDAQ: GNPX) surged 11.37% in after-hours trading following announcements that the Japanese and European Patent Offices granted patents for its REQORSA gene therapy in combination with PD-1/PD-L1 immunotherapies. These approvals expand IP protection for the company’s Acclaim-3 clinical trial targeting small cell lung cancer, reinforcing its global intellectual property portfolio. The patents align with ongoing Phase 2 expansion of Acclaim-3, which received FDA Fast Track and Orphan Drug designations, and build on existing U.S. and Korean patents. The news underscores Genprex’s progress in solidifying proprietary rights for its oncology pipeline, enhancing its competitive positioning and potential commercial viability for REQORSA-based therapies.